OpenNeedle Ask your own

Question explored with the scientific record

Was the Covid vaccine more harmful than good

Sep 24, 2026 · 12 sources used · OpenNeedle synthesis
The evidence on whether COVID-19 vaccines caused more harm than good is deeply conflicted, with the answer depending heavily on age, time since vaccination, and which study you trust.

The strongest evidence for net benefit comes from large population studies that adjusted for the "healthy vaccinee" effect, where healthier people are more likely to get vaccinated. A Norwegian study of 4.6 million adults found that those with three or more mRNA doses had about a 60% lower all-cause mortality rate than unvaccinated people across all age groups [3]. A Hungarian study of 6.4 million adults, which explicitly corrected for the healthy vaccinee bias, found all six vaccines reduced all-cause mortality by 49-75% during the epidemic wave [4]. A Danish study of heart failure patients found a small but significant mortality reduction after vaccination [7].

But several other studies point in the opposite direction. A UK analysis of ONS data found that all-cause mortality in vaccinated people started lower but then rose over time, crossing the unvaccinated rate between September 2022 and January 2025 depending on age group [2]. A US county-level study of over 3,000 counties found that higher vaccination rates were associated with more excess mortality in 2022 and 2023, estimating that 130,000 to 180,000 US deaths between February and August 2021 could be attributed to vaccination [1, 8]. A European ecological study of 31 countries found that higher 2021 vaccination uptake was linked to larger increases in monthly excess mortality in 2022 [5].

The studies that show harm are mostly ecological or observational, meaning they cannot prove causation. The studies that show benefit are also observational and may still suffer from residual confounding. The Norwegian study, for example, acknowledged that unmeasured factors like low socioeconomic status could bias results [3]. The UK ONS study attributed much of its early mortality difference to selection bias [6].

StudyPopulationKey FindingDesign Limitation
Norway (2026) [3]4.6M adults, 2021-202360% lower all-cause mortality with 3+ dosesResidual confounding possible
Hungary (2022) [4]6.4M adults, 202149-75% lower mortality, HVE-correctedNonepidemic period not fully virus-free
UK ONS (2025) [2]England adults, 2021-2023Mortality crossed from lower to higher in vaccinatedSelection bias acknowledged
US counties (2026) [1]3,000+ counties, 2022-2023Higher vaccination linked to more excess mortalityEcological, cannot prove causation
Europe (2023) [5]31 countries, 2022Higher vaccination linked to more monthly excess deathsEcological fallacy possible

The myocarditis risk is real but rare: about 1-4 cases per 100,000 vaccinated, mostly in young males after the second mRNA dose, and the disease course is usually mild [10, 12]. COVID-19 infection itself carries a much higher myocarditis risk [9, 11].

My call: the evidence does not support a blanket "more harmful than good" verdict. For older adults during the peak pandemic, the vaccines likely reduced mortality. For younger people, especially males, the risk-benefit is much closer and may have shifted to net harm over time as the virus became less deadly. Confidence: moderate.

Keep digging

Sources used 12

  1. Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people F1000Research (2026) primary study Strong

    A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.

    DOI: 10.12688/f1000research.177279.1
  2. All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data F1000Research (2025) primary study Strong

    The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…

    DOI: 10.12688/f1000research.154058.2
  3. COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study BMJ Public Health (2026) primary study Strong

    In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…

    DOI: 10.1136/bmjph-2024-001859
  4. Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study Vaccines (2022) primary study Strong

    In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…

    DOI: 10.3390/vaccines10071009
  5. Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality? Asian Pacific Journal of Health Sciences (2023) primary study Strong

    Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…

    DOI: 10.21276/apjhs.2023.10.1.6
  6. All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data F1000Research (2024) primary study Strong

    Using UK ONS data, the paper reports higher all-cause and non-COVID mortality among vaccinated than unvaccinated, attributes much of it to selection bias, and concludes third/fourth doses appear ineffective for under-70s.

    DOI: 10.12688/f1000research.154058.1
  7. Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study European Heart Journal (2022) primary study Strong

    In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…

    DOI: 10.1093/eurheartj/ehac544.881
  8. COVID Vaccination and Age-Stratified All-Cause Mortality Risk International Journal of Vaccine Theory, Practice, and Research (2025) primary study Strong

    US and European ecological analyses linked COVID vaccination rates to increased all-cause mortality within 0-5 weeks and to increased mortality in unvaccinated children; estimated US vaccine mortality rate was 0.04%, with 130K-180K deaths (Feb-Aug 2021).

    DOI: 10.56098/rbvsmw07
  9. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms Nature Reviews Cardiology (2021) Thin

    This study examines the incidence and implications of acute myocarditis associated with COVID-19 mRNA vaccination compared to myocarditis resulting from COVID-19 infection, highlighting the rarity of vaccine-related myocarditis and the greater risks associated with COVID-19 itse…

    DOI: 10.1038/s41569-021-00662-w
  10. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review BMJ (2022) systematic review Strong

    This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…

    DOI: 10.1136/bmj-2021-069445
  11. Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis American Journal of Health, Medicine and Nursing Practice (2023) meta-analysis Strong

    In a meta-analysis of four observational studies, BNT162b2-associated myocarditis in adolescents was rare, with male predominance and higher incidence after the second dose.

    DOI: 10.47672/ajhmn.1387
  12. The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis Netherlands Heart Journal (2022) narrative review Strong

    COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.

    DOI: 10.1007/s12471-022-01677-9

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question